ABSTRACT C-Myc overexpression is a common finding in pancreatic cancer and predicts
the aggressive behavior of cancer cells. It binds to the promoter of different genes, thereby …

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy characterized by
high resistance and poor response to chemotherapy. In addition, the poorly immunogenic …

Pharmacological inhibition of KRAS> RAF> MEK1/2> ERK1/2 signaling has provided no
clinical benefit to patients with pancreatic ductal adenocarcinoma (PDAC). Interestingly …

Microscopy is a powerful tool for characterizing complex cellular phenotypes, but linking
these phenotypes to genotype or RNA expression at scale remains challenging. Here, we …

In recent years, a growing number of studies have evaluated the role of exosomes in
pancreatic ductal adenocarcinoma cancer (PDAC) demonstrating their involvement in a …

Tumor heterogeneity is a major challenge for oncology drug discovery and development.
Understanding of the spatial tumor landscape is key to identifying new targets and impactful …

The small GTPase KRAS is frequently mutated in pancreatic cancer and its cooperation with
the transcription factor MYC is essential for malignant transformation. The key to oncogenic …

Despite favorable responses to initial chemotherapy, drug resistance is a major cause
limiting chemotherapeutic efficacy in many advanced cancers. However, mechanisms that …

Cancer is the second leading cause of death in the world. Given that cancer is a highly
individualized disease, predicting the best chemotherapeutic treatment for individual …

Paclitaxel (PTX) is one of standard chemotherapy drug for patients with metastatic castration-
resistant prostate cancer (mCRPC). However, PTX resistance leads to treatment failures, for …